Grifols Egypt continues its growth plan through 2029 with an additional investment of €180 million

Barcelona, June 12, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and a leader in the production of plasma-derived medicines, has announced that Grifols Egypt for Plasma Derivatives (GEPD), its joint venture with the Government of Egypt to deploy the country’s, Africa’s, and the Middle East’s first fully integrated plasma ecosystem, has launched its 2026–2029 growth plan with an additional investment of €180 million.

This new investment strengthens the progress of Egypt’s national and international program for self-sufficiency in plasma-derived medicines and consolidates the country’s role as a strategic platform within Grifols’ global plasma supply network. This amount will be added to the €280 million invested to date in the project’s development and will help accelerate the expansion of the national network of plasma centers, reinforce industrial capacity, and advance the goal of progressively increasing plasma collection capacity to three million liters by 2029.

The company continues to work to consolidate the entire value chain for the manufacturing of national plasma-derived medicines within Egypt, thereby ensuring their supply to the entire Egyptian population and the region. Currently, Grifols Egypt operates 16 donation centers in Egypt, with four additional centers planned for 2026. Once this network of 20 centers is completed, the company expects to continue expanding its national network, which will progressively increase plasma collection capacity.

According to Tomás Dagá, Vice Chairman of the Board of Grifols Egypt: “We are demonstrating that it is possible, together with institutions, to build a solid model based on local plasma for patients in the country, capable of transforming it into essential therapies through international standards and a safe, traceable, and robust value chain. We are convinced that well-developed regional systems, supported by industrial capacity, are essential to reduce external dependencies and help sustainably ensure access to plasma-derived medicines.”

Dagá added: “This is why Grifols Egypt has approved the launch of a new growth plan involving an additional investment of €180 million between 2026 and 2029, with the aim of accelerating the development of the industrial infrastructure needed to consolidate Egypt’s self-sufficiency in plasma-derived medicines. The new plan reaffirms Grifols’ commitment to industrial and social development in Egypt, where the company will have invested €460 million since the project began.”

This initiative represents one of the most ambitious examples of healthcare and industrial transformation driven through public-private collaboration in the Middle East and Africa. Established in 2020, GEPD is jointly owned by the National Service Projects Organization, representing the Egyptian state, and Grifols, and aims to build a complete value chain for the collection, testing, processing, and future local production of plasma-derived medicines.

The complex, which the company is building in the New Administrative Capital and whose first phase is expected to be inaugurated in the fall of 2026, will include a new processing plant designed to handle more than one million liters of plasma per year. In addition, it will feature a comprehensive plasma logistics center that will ensure full traceability and maximum control across the entire value chain, as has been the case in all Grifols operations since 1971.

These facilities include the first automated plasma testing laboratory in the Middle East and Africa, which will enhance quality and safety controls, ensure the traceability of donations, and support the progressive expansion of the industrial project in the country.

An unprecedented economic, social, and healthcare impact

The public-private partnership between Grifols and the Government of Egypt has made it possible, in record time, to create Africa’s first fully integrated plasma ecosystem and one of the most advanced in the world.

Over these five years, the initiative has had a significant impact on the country’s healthcare system: more than 1.6 million vials produced with Egyptian plasma have been delivered to hospitals and public health centers, and over 120,000 free medical check-ups have been provided to donors. The cumulative clinical impact of plasma therapies exceeds €80 million in health benefits, thanks to more diagnoses, more treatments, and greater preventive capacity.

In addition, Egypt has strengthened its healthcare infrastructure through collaborations with the World Federation of Hemophilia (WFH) and the International Patient Organisation for Primary Immunodeficiencies (IPOPI), enabling the promotion of training programs and the donation of coagulation factors that enhance the system’s autonomy and resilience.

From an economic and social perspective, the project has become a national driving force. In 2025, Grifols, through Grifols Egypt, contributed €55 million to Egypt’s GDP and is expected to reach an estimated annual contribution of over €272 million by 2030. During the 2026–2029 growth plan, direct investments will generate a total impact exceeding €700 million, as a result of the project’s direct, indirect, and induced effects. This development is also reflected in employment: to date, more than 1,500 highly qualified direct jobs have been created, along with over 14,000 indirect and induced jobs; and between 2026 and 2029, a total of 186,000 new jobs are expected to be generated.

Developing local capabilities is another key pillar of the project. The Grifols Academy for Plasmapheresis, the first institution in Africa dedicated to this technical training, has delivered more than 170,000 hours of instruction under international standards and has prepared Egyptian personnel to operate the system with full autonomy. This is complemented by collaborations with national universities to train specialized professionals and strengthen an independent professional ecosystem.

Egypt, a key pillar in Grifols’ global strategy

Grifols’ project in Egypt reinforces the company’s commitment to a more diversified and resilient supply model. Based on the collection of local plasma to meet the needs of patients in the country, Egypt has positioned itself as a regional hub to supply Africa and the Middle East with surplus plasma-derived products.

Likewise, following the European Medicines Agency (EMA)’s approval in December 2025 of Grifols Egypt’s entire value chain in Egypt, it ensures that medicines produced from plasma collected in the country can be supplied to other markets once domestic needs have been met. This model helps to progressively reduce dependence on plasma sourced from the United States. Until now, the plasma-derived medicines industry has relied heavily on the U.S., which has supplied 65% of global plasma needs.

In Europe, more than 40% of the plasma used to manufacture medicines comes from the United States. This strong external dependence highlights the system’s vulnerability to potential supply disruptions. The EMA’s certification of the Grifols Egypt project is therefore of strategic importance: it positions Egypt, together with Grifols, as a new healthcare hub capable of helping to strengthen plasma supply security in Europe.

This regulatory recognition aligns with the priorities of the new SoHo (Substances of Human Origin) regulation, which highlights the need to ensure a stable supply of plasma-derived medicines. In this context, Grifols Egypt, under the “Grifols seal,” adds to Grifols’ existing capacity to improve the supply of the European market.

About Grifols Egypt for Plasma Derivatives (GEPD)

GEPD is a joint venture between Grifols and the Government of Egypt, created to develop a national plasma platform, drive the country’s self-sufficiency in plasma-derived medicines, and build local capabilities under international standards of quality, safety, and traceability. The project integrates donation centers, testing laboratories, logistics facilities, specialized training, and industrial capabilities to advance toward the local production of plasma-derived medicines.